# Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer

> **NCT02751710** · NA · COMPLETED · sponsor: **Ontario Clinical Oncology Group (OCOG)** · enrollment: 369 (actual)

## Conditions studied

- Stage III Breast Cancer (T0N2, T1N2, T2N2, T3N1, 2 or T4)
- Stage IIb Breast Cancer (T3N0)

## Interventions

- **OTHER:** Whole-body FDG PET-CT alone

## Key facts

- **NCT ID:** NCT02751710
- **Lead sponsor:** Ontario Clinical Oncology Group (OCOG)
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-06
- **Primary completion:** 2023-03-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 369 (ACTUAL)
- **Last updated:** 2024-01-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02751710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02751710, "Impact of 18F-FDG PET-CT Versus Conventional Staging in the Management of Patients Presenting With Clinical Stage III Breast Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT02751710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*